Health Canada approves Pfizer-BioNtech COVID-19 vaccine for kids aged 5-11 - The Globe and Mail | Canada News Media
Connect with us

Business

Health Canada approves Pfizer-BioNtech COVID-19 vaccine for kids aged 5-11 – The Globe and Mail

Published

 on


Children aged 5 and older are now eligible to be vaccinated against COVID-19 for the first time in Canada, a key milestone that can help families return to some prepandemic ways of life, Health Canada’s chief medical adviser announced on Friday.

“Overall, this is very good news for adults and children alike. It provides another tool to protect Canadians and, to the relief of many parents, will help bring a degree of normality back to children’s lives,” Dr. Supriya Sharma said on Friday.

Pediatric COVID-19 vaccines will start to arrive in Canada on Sunday, with 2.9 million doses – enough to provide a first dose to every five- to 11-year-old in Canada – expected to be delivered by the end of next week, Public Services and Procurement Minister Filomena Tassi announced Friday. The timing on delivery of second doses has yet to be determined, Ms. Tassi said.

What to know about the Pfizer COVID-19 vaccine for kids aged 5-11: efficacy, side effects and more

The authorization comes at a critical time in the pandemic, as the incidence rate of COVID-19 among those aged 5 to 11 is currently higher than in any other age group, said Theresa Tam, Canada’s Chief Public Health Officer. While most children will fully recover from COVID-19, a small number are at risk for serious cases and long-lasting severe health problems, including multisystem inflammatory syndrome, long COVID and other issues.

Marie Tarrant, a professor in the school of nursing at the University of British Columbia, said vaccinating school-aged children could go a long way to controlling spread of COVID-19.

“There is a lot of anticipation and expectation that this will help us curb some of these outbreaks that we’ve been having,” she said.

The newly authorized mRNA vaccine, produced by Pfizer-BioNTech, is a 10-microgram dosage – which is one-third the amount used in the adult version. Children tend to produce strong immune responses, which is why a smaller dose is being used. A clinical trial showed the vaccine is about 91 per cent effective after two doses and no serious side effects were reported. Canadian regulators will closely monitor for any reports of adverse events as the vaccine is rolled out.

Health Canada authorized two doses of the Pfizer-BioNTech vaccine for kids 5 to 11, to be given three weeks apart – the same dosing interval used in the clinical trial.

But the National Advisory Committee on Immunization is recommending that kids wait eight weeks between the first and second dose in order to maximize the immune response. Evidence also shows that cases of heart inflammation, a rare side effect linked to the COVID-19 mRNA vaccines, are also lower when doses are spaced farther apart. Although NACI’s guidelines aren’t binding, provinces typically follow the recommendations, which are based on science and real-world evidence.

Dr. Sharma said there may be a need for more flexibility on dosing schedules. The holidays are approaching and many families want to celebrate together or enjoy travel as safely as possible. For that reason, health professionals may want to consider offering first and second doses more closely together than the eight-week timeline, Dr. Sharma said.

“I think it really is a discussion with health care practitioners,” Dr. Sharma said. “I think all of that needs to be considered as people are making their vaccination choices.”

NACI is also recommending that the COVID-19 shot not be combined with other vaccines for the time being. They say five- to 11-year-olds should not receive another vaccine for two weeks before or after their COVID-19 shot to help regulators monitor the safety of the vaccine and more easily determine if any reported side effects are linked to it.

Officials noted that it’s safe to combine vaccines, such as the flu shot and the COVID-19 shot, and there may be instances, such as during this year’s influenza season, when children are advised to receive both together.

The most common side effects linked to the newly authorized COVID-19 vaccine are soreness at the injection site, fatigue and headache.

The mRNA vaccines have been linked to rare cases of heart inflammation, or myocarditis and pericarditis, primarily in young men after the second dose. Most of the cases are mild and resolve with medication.

While no cases of heart inflammation were reported in children during the clinical trial, it’s possible some may occur, Dr. Sharma said, which is why officials will be closely watching for any side effects. She noted that the health risks of COVID-19 are much higher than any risks linked to the vaccine.

Now that the shot has been approved, provincial and local health officials across Canada are readying plans to start the largest mass vaccination campaign in children in decades.

Clinical studies with children under the age of 5 are continuing, but a COVID-19 vaccine for that age group is not expected until some time next year.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Adblock test (Why?)



Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version